Zymeworks recently received clearance from the FDA for its first randomized Phase 3 clinical trial for zanidatamab. HERIZON-GEA-01 is a randomized, multicenter study of zanidatamab in combination with chemotherapy with… Read More
Meet ‘Ready-to-Raise’ ventures, from our later stage incubator and HATCH Accelerator, at our upcoming 2021 Investor Showcase! The Investor Showcase spotlights high-potential, investible ventures currently supported through entrepreneurship@UBC and the… Read More
Patents granted in the United States, China, South Korea, Japan, Israel and New Zealand for dermal injector and tendon regeneration technologies VANCOUVER, BC – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV:… Read More
We are pleased to announce Axotol Instruments as 1 of 11 innovative companies that will participate in this year’s Canadian Technology Accelerator (CTA) in Boston. The CTA Boston 2021 Cohort… Read More
Vancouver, BC – May 4th, 2021 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development… Read More
